Oppenheimer reiterated their hold rating on shares of Acceleron Pharma (NASDAQ:XLRN) in a report released on Monday morning.

XLRN has been the subject of a number of other research reports. Credit Suisse Group set a $51.00 target price on shares of Acceleron Pharma and gave the stock a buy rating in a research report on Tuesday, November 14th. ValuEngine downgraded shares of Acceleron Pharma from a hold rating to a sell rating in a research report on Friday, October 6th. Barclays increased their price objective on shares of Acceleron Pharma from $42.00 to $50.00 and gave the company an overweight rating in a research report on Wednesday, September 20th. Cann reaffirmed a hold rating on shares of Acceleron Pharma in a research report on Tuesday, September 5th. Finally, HC Wainwright started coverage on shares of Acceleron Pharma in a research report on Thursday, October 12th. They issued a buy rating and a $57.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Acceleron Pharma currently has a consensus rating of Buy and an average target price of $44.56.

Acceleron Pharma (NASDAQ XLRN) opened at $36.00 on Monday. Acceleron Pharma has a one year low of $23.07 and a one year high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.02. The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.52 million. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The company’s revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.55) EPS. sell-side analysts expect that Acceleron Pharma will post -2.65 earnings per share for the current year.

In other news, major shareholder Corp /De/ Celgene acquired 745,592 shares of Acceleron Pharma stock in a transaction that occurred on Monday, September 25th. The shares were purchased at an average cost of $37.00 per share, for a total transaction of $27,586,904.00. Following the completion of the purchase, the insider now directly owns 6,118,479 shares of the company’s stock, valued at approximately $226,383,723. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.90% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in XLRN. Teachers Advisors LLC lifted its stake in Acceleron Pharma by 2.1% during the first quarter. Teachers Advisors LLC now owns 46,080 shares of the biopharmaceutical company’s stock worth $1,220,000 after purchasing an additional 942 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Acceleron Pharma by 5.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 131,841 shares of the biopharmaceutical company’s stock valued at $3,490,000 after buying an additional 7,335 shares during the last quarter. TD Asset Management Inc. lifted its stake in Acceleron Pharma by 0.8% in the second quarter. TD Asset Management Inc. now owns 78,800 shares of the biopharmaceutical company’s stock valued at $2,395,000 after buying an additional 600 shares during the last quarter. Rhumbline Advisers lifted its stake in Acceleron Pharma by 15.3% in the second quarter. Rhumbline Advisers now owns 37,217 shares of the biopharmaceutical company’s stock valued at $1,131,000 after buying an additional 4,945 shares during the last quarter. Finally, State of Wisconsin Investment Board bought a new stake in Acceleron Pharma in the second quarter valued at $699,000. Hedge funds and other institutional investors own 85.84% of the company’s stock.

WARNING: “Acceleron Pharma’s (XLRN) “Hold” Rating Reiterated at Oppenheimer” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/15/acceleron-pharmas-xlrn-hold-rating-reiterated-at-oppenheimer.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Stock Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related stocks with our FREE daily email newsletter.